Redeye reiterates its Base case valuation of SEK 4.5 after the news that InDex has signed a CRO-agreement with Parexel Biotech; there is a clear rationale to partner with the same CRO as in the successful CONDUCT-study. We consider today's news as further validation of InDex's timeline regarding the CONCLUDE-study initiation during the second quarter of this year.